Edgewise Therapeutics Q2 EPS $(0.34) Beats $(0.36) Estimate
Portfolio Pulse from Benzinga Newsdesk
Edgewise Therapeutics (NASDAQ:EWTX) reported a Q2 EPS of $(0.34), beating the analyst estimate of $(0.36) by 5.56%. This result is unchanged from the same period last year.
August 08, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edgewise Therapeutics reported a Q2 EPS of $(0.34), beating the analyst estimate of $(0.36) by 5.56%. This result is unchanged from the same period last year.
Edgewise Therapeutics' Q2 EPS beat analyst expectations, which is generally a positive indicator for the stock price. However, the result is unchanged from last year, which may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100